Terms: = Bone cancer AND JAK2, ENSG00000096968, O60674, JTK10, 3717 AND Prognosis
76 results:
1. Secondary Polycythemia and Non-Islet Cell Tumor-induced Hypoglycemia in Advanced Hepatocellular Carcinoma: A Case Report.
Paramitha MS; Esa DF; Hustrini NM; Mulansari NA; Hasan I; Harahap AS
Acta Med Indones; 2024 Jan; 56(1):93-101. PubMed ID: 38561874
[TBL] [Abstract] [Full Text] [Related]
2. Exploring the Molecular Aspects of Myeloproliferative Neoplasms Associated with Unusual Site Vein Thrombosis: Review of the Literature and Latest Insights.
Morsia E; Torre E; Martini F; Morè S; Poloni A; Olivieri A; Rupoli S
Int J Mol Sci; 2024 Jan; 25(3):. PubMed ID: 38338802
[TBL] [Abstract] [Full Text] [Related]
3. Essential thrombocythemia: 2024 update on diagnosis, risk stratification, and management.
Tefferi A; Vannucchi AM; Barbui T
Am J Hematol; 2024 Apr; 99(4):697-718. PubMed ID: 38269572
[TBL] [Abstract] [Full Text] [Related]
4. Allogeneic hematopoietic cell transplantation in patients with CALR-mutated myelofibrosis: a study of the Chronic Malignancies Working Party of EBMT.
Hernández-Boluda JC; Eikema DJ; Koster L; Kröger N; Robin M; de Witte M; Finke J; Finazzi MC; Broers A; Raida L; Schaap N; Chiusolo P; Verbeek M; Hazenberg CLE; Halaburda K; Kulagin A; Labussière-Wallet H; Gedde-Dahl T; Rabitsch W; Raj K; Drozd-Sokolowska J; Battipaglia G; Polverelli N; Czerw T; Yakoub-Agha I; McLornan DP
Bone Marrow Transplant; 2023 Dec; 58(12):1357-1367. PubMed ID: 37679647
[TBL] [Abstract] [Full Text] [Related]
5. Diagnosis- and prognosis-Related Gene Alterations in
Morishita S; Komatsu N
Int J Mol Sci; 2023 Aug; 24(16):. PubMed ID: 37629188
[No Abstract] [Full Text] [Related]
6. Co-occurring mutations in ASXL1, SRSF2, and SETBP1 define a subset of myelodysplastic/ myeloproliferative neoplasm with neutrophilia.
Jain T; Ware AD; Dalton WB; Pasca S; Tsai HL; Gocke CD; Gondek LP; Xian RR; Borowitz MJ; Levis MJ
Leuk Res; 2023 Aug; 131():107345. PubMed ID: 37354804
[TBL] [Abstract] [Full Text] [Related]
7. The international consensus classification of eosinophilic disorders and systemic mastocytosis.
Wang SA; Orazi A; Gotlib J; Reiter A; Tzankov A; Hasserjian RP; Arber DA; Tefferi A
Am J Hematol; 2023 Aug; 98(8):1286-1306. PubMed ID: 37283522
[TBL] [Abstract] [Full Text] [Related]
8. [Prognostic analysis of children with Philadelphia chromosome-like acute lymphoblastic leukemia common genes].
Hu WD; Li B; Su SF; Liu YF; Liu W; Zhang WL; Zuo WL; Yu RH
Zhonghua Er Ke Za Zhi; 2023 May; 61(5):446-452. PubMed ID: 37096265
[No Abstract] [Full Text] [Related]
9. Clonal Hematopoiesis of Indeterminate Potential: Current Understanding and Future Directions.
Singh I; Singh A
Curr Oncol Rep; 2023 Jun; 25(6):539-547. PubMed ID: 36928826
[TBL] [Abstract] [Full Text] [Related]
10. jak2V617F variant allele frequency, non-driver mutations, single-nucleotide variants and polycythemia vera outcome.
Kanduła Z; Janowski M; Więckowska B; Paczkowska E; Lewandowski K
J Cancer Res Clin Oncol; 2023 Jul; 149(8):4789-4803. PubMed ID: 36242602
[TBL] [Abstract] [Full Text] [Related]
11. Myeloid Sarcoma of the Breast as Blast Phase of jak2-Mutated (Val617Phe Exon 14p) Essential Thrombocythemia: A Case Report and a Systematic Literature Review.
Pace M; Guadagno E; Russo D; Gencarelli A; Carlea A; Di Spiezio A; Bertuzzi C; Mascolo M; Grimaldi F; Insabato L
Pathobiology; 2023; 90(2):123-130. PubMed ID: 35850113
[TBL] [Abstract] [Full Text] [Related]
12. Clinicopathologic spectrum of myeloid neoplasms with concurrent myeloproliferative neoplasm driver mutations and SRSF2 mutations.
Tashakori M; Khoury JD; Routbort MJ; Patel KP; Wang SA; Ok CY; El-Hussein S; Kanagal-Shamanna R; Luthra R; Hu S; Lin P; Pemmaraju N; Bose P; Verstovsek S; Bueso-Ramos CE; Medeiros LJ; Loghavi S
Mod Pathol; 2022 Nov; 35(11):1677-1683. PubMed ID: 35690645
[TBL] [Abstract] [Full Text] [Related]
13. How I Diagnose Primary Myelofibrosis.
Prakash S; Orazi A
Am J Clin Pathol; 2022 Apr; 157(4):518-530. PubMed ID: 35238345
[TBL] [Abstract] [Full Text] [Related]
14. Thrombocytopenia in Patients With Myelofibrosis: Pathogenesis, Prevalence, Prognostic Impact, and Treatment.
Sastow D; Mascarenhas J; Tremblay D
Clin Lymphoma Myeloma Leuk; 2022 Jul; 22(7):e507-e520. PubMed ID: 35221248
[TBL] [Abstract] [Full Text] [Related]
15. Mutational landscape of blast phase myeloproliferative neoplasms (MPN-BP) and antecedent MPN.
Pasca S; Chifotides HT; Verstovsek S; Bose P
Int Rev Cell Mol Biol; 2022; 366():83-124. PubMed ID: 35153007
[TBL] [Abstract] [Full Text] [Related]
16. Myelofibrosis: Genetic Characteristics and the Emerging Therapeutic Landscape.
Tefferi A; Gangat N; Pardanani A; Crispino JD
Cancer Res; 2022 Mar; 82(5):749-763. PubMed ID: 34911786
[TBL] [Abstract] [Full Text] [Related]
17. [Clinical impact of gene mutations on myeloproliferative neoplasms in Japan].
Morishita S
Rinsho Ketsueki; 2021; 62(8):1060-1069. PubMed ID: 34497192
[TBL] [Abstract] [Full Text] [Related]
18. CDK6 Is a Therapeutic Target in Myelofibrosis.
Dutta A; Nath D; Yang Y; Le BT; Mohi G
Cancer Res; 2021 Aug; 81(16):4332-4345. PubMed ID: 34145036
[TBL] [Abstract] [Full Text] [Related]
19. Clinical and histopathological features of myeloid neoplasms with concurrent Janus kinase 2 (jak2) V617F and KIT proto-oncogene, receptor tyrosine kinase (KIT) D816V mutations.
Naumann N; Lübke J; Shomali W; Reiter L; Horny HP; Jawhar M; Dangelo V; Fabarius A; Metzgeroth G; Kreil S; Sotlar K; Oni C; Harrison C; Hofmann WK; Cross NCP; Valent P; Radia D; Gotlib J; Reiter A; Schwaab J
Br J Haematol; 2021 Jul; 194(2):344-354. PubMed ID: 34060083
[TBL] [Abstract] [Full Text] [Related]
20. Accelerated Phase of Myeloproliferative Neoplasms.
Shahin OA; Chifotides HT; Bose P; Masarova L; Verstovsek S
Acta Haematol; 2021; 144(5):484-499. PubMed ID: 33882481
[TBL] [Abstract] [Full Text] [Related]
[Next]